Sionna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-75.27	-61.69	-47.26	-40.24
Depreciation & Amortization	0.65	0.67	0.58	0.12
Stock-Based Compensation	12.07	3.71	2.26	1.69
Other Adjustments	-1.09	7.6	1.51	-0.4
Changes in Accounts Payable	-0.42	0.47	0.16	-1.51
Changes in Accrued Expenses	1.98	1.08	-1.11	5.03
Changes in Other Operating Activities	-4.21	-4.62	0.16	-0.75
Operating Cash Flow	-66.3	-52.79	-43.7	-36.07
Capital Expenditures	-0.38	-0.03	-1.12	-1.87
Purchases of Investments	-325.03	-182.84	-23.53	-40.39
Proceeds from Sale of Investments	206.65	55.96	52	13
Investing Cash Flow	-118.75	-126.91	27.35	-29.26
Issuance of Common Stock	205.71	0.14	0.03	0.06
Net Common Stock Issued (Repurchased)	205.71	0.14	0.03	0.06
Issuance of Preferred Stock	-	181.33	-	110.79
Net Preferred Stock Issued (Repurchased)	-	181.33	-	110.79
Other Financing Activities	-	-2.5	-	-
Financing Cash Flow	205.71	178.97	0.03	110.86
Net Cash Flow	20.66	-0.73	-16.32	45.52
Free Cash Flow	-66.67	-52.81	-44.82	-37.94
Free Cash Flow Per Share	-1.67	-13.69	-15.28	-0.01
Levered Free Cash Flow	-77.65	-64.12	-48.58	-39.23
Unlevered Free Cash Flow	-91.36	-72.99	-51.65	-40.36

Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q